Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04208412 · ClinicalTrials.gov registry record · Phase 2

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

A Phase 2 study of Hereditary Angioedema, sponsored by KalVista Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
84
Enrollment target
20
Study locations

NCT04208412 is a Phase 2 study of Hereditary Angioedema that has completed, run by KalVista Pharmaceuticals. The registered enrollment target is 84 participants, above the 70-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04208412, a Phase 2 study of Hereditary Angioedema, has completed, sponsored by KalVista Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
84 participants
Enrollment target
20
Study locations

Study Summary

This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.

Conditions Studied

Hereditary Angioedema

Interventions

  • OTHER Placebo
  • DRUG KVD900

Study Locations (20)

Other

  • KalVista Investigative Site - Vienna
  • KalVista Investigative Site - Brno
  • KalVista Investigative Site - Hradec Králové
  • KalVista Investigative Site - Pilsen
  • KalVista Investigative Site - Berlin
  • KalVista Investigative Site - Frankfurt
  • KalVista Investigative Site - Mörfelden-Walldorf
  • KalVista Investigative Site - Budapest
  • KalVista Investigative Site - Milan
  • KalVista Investigative Site - Milano-2
  • KalVista Investigative Site - Padua
  • KalVista Investigative Site - Amsterdam
  • KalVista Investigative Site - Skopje
  • KalVista Investigative Site - Krakow

Arizona

  • KalVista Investigative Site - Scottsdale

Colorado

  • KalVista Investigative Site - Centennial

Maryland

  • KalVista Investigative Site - Chevy Chase

Ohio

  • KalVista Investigative Site - Cincinnati

Texas

  • KalVista Investigative Site - Dallas

Washington

  • KalVista Investigative Site - Spokane

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2019-07-02
Est. Completion 2020-12-08
Phase Phase 2

Sponsor

KalVista Pharmaceuticals

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04208412

The ClinicalTrials.gov registry entry for NCT04208412 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 70-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (20% higher). The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04208412 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT04208412 about?

NCT04208412 is a clinical study titled "A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II". This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.

What is the current status of trial NCT04208412?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2019-07-02. Estimated completion is 2020-12-08.

What conditions does trial NCT04208412 study?

This clinical trial studies the following conditions: Hereditary Angioedema.

What interventions are being tested in trial NCT04208412?

The interventions under investigation include: Placebo (OTHER), KVD900 (DRUG).

Who is sponsoring clinical trial NCT04208412?

This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04208412 being conducted?

This trial has 20 study locations across Arizona, Colorado, Maryland, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hereditary Angioedema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hereditary Angioedema

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.